穴位贴敷疗法联合运动处方治疗非酒精性脂肪性肝病患者疗效初步研究*

doi:10.3969/j.issn.1672-5069.2025.02.012

摘要/Abstract

摘要： 目的探讨穴位贴敷疗法联合运动处方治疗非酒精性脂肪性肝病(NAFLD)患者的疗效。方法 2022年1月～2024年3月我院诊治的NAFLD患者119例,被分为对照组59例和联合组60例,分别给予运动处方或在运动处方的基础上联合穴位贴敷疗法治疗,均治疗3个月。测量体质量、腰围、体脂率(BFP),计算体质指数(BMI)和腰臀比(WHR)。采用双抗体夹心ELISA法检测血清瘦素、脂联素、抵抗素、肿瘤坏死因子-α(TNF-α)和白介素-6(IL-6)。结果在治疗3个月末,联合组体质量、BMI和BFP分别为(62.3±7.8)kg、(24.5±3.3)kg/m²和(29.2±3.6)%,均显著低于对照组【分别为(68.2±8.9)kg、(26.8±2.8)kg/m²和(31.7±3.9)%,P<0.05】;血清TG和LDL-C水平分别为(2.1±0.3)mmol/L和(2.3±0.5)mmol/L,均显著低于对照组【分别为(2.9±0.3)mmol/L和(2.8±0.7)mmol/L,P<0.05】,而血清HDL-C水平为(1.3±0.3)mmol/L,显著高于对照组【(1.1±0.3)mmol/L,P<0.05】;血清ALT、AST和GGT水平分别(45.1±8.7)U/L、(41.5±8.0)U/L和(38.7±7.8)U/L,均显著低于对照组【分别为(56.8±7.3)U/L、(52.4±6.6)U/L和(46.2±8.5)U/L,P<0.05】;血清瘦素、抵抗素、TNF-α和IL-6水平分别为(9.7±2.1)pg/mL、(9.8±3.9)ng/mL、(21.2±5.2)ng/L和(20.1±2.3)mg/L,均显著低于对照组【分别为(11.8±2.0)pg/mL、(13.2±4.3)ng/mL、(27.8±4.7)ng/L和(27.5±2.7)mg/L,P<0.05】,而血清脂联素水平为(3.1±1.0)ng/mL,显著高于对照组【(2.5±0.8)ng/mL,P<0.05】。结论采取穴位贴敷疗法联合运动处方治疗NAFLD患者可以收到较好的短期疗效,体质量下降,血脂水平降低,可能与抑制了机体炎性反应有关。

关键词: 非酒精性脂肪性肝病, 穴位贴敷, 运动处方, 治疗

Abstract: Objective The aim of this study was to investigate short-term efficacy of acupoint application at base of sport exercise in the treatment of patients with non-alcoholic fatty liver disease (NAFLD). Methods 119 patients with NAFLD were encountered in our hospital between January 2022 and March 2024, and were randomly divided into control (n=59) and combination group (n=60), receiving sport exercise under guidance or acupoint application at base of sport exercise for 3 months. Weight, waist circumference, and body fat percentage (BFP) were measured, and body mass index (BMI) and waist to hip ratio (WHR) were calculated. Serum leptin, adiponectin, resistin, tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) levels were assayed by ELISA. Results By end of 3 months of treatment, body weight, BMI and BFP in combination group were (62.3±7.8)kg, (24.5±3.3)kg/m² and (29.2±3.6)%, all significantly lower than [(68.2±8.9)kg,(26.8±2.8)kg/m² and (31.7±3.9)%, respectively, P<0.05] in the control; serum TG and LDL-C levels were (2.1±0.3)mmol/L and (2.3±0.5)mmol/L, both significantly lower than [(2.9±0.3)mmol/L and(2.8±0.7)mmol/L, P<0.05], while serum HDL-C level was (1.3±0.3) mmol/L, significantly higher than [(1.1±0.3)mmol/L, P<0.05] in the control group; serum ALT, AST and GGT levels were (45.1±8.7)U/L, (41.5±8.0)U/L and (38.7±7.8)U/L, all much lower than [(56.8±7.3)U/L, (52.4±6.6)U/L and (46.2±8.5)U/L, respectively, P<0.05] in the control; serum leptin, resistin, TNF-α and IL-6 levels were (9.7±2.1)pg/mL, (9.8±3.9)ng/mL, (21.2±5.2)ng/L and (20.1±2.3)mg/L, all much lower than [(11.8±2.0)pg/mL, (13.2±4.3)ng/mL, (27.8±4.7)ng/L and (27.5±2.7)mg/L, respectively, P<0.05], while serum adiponectin level was (3.1±1.0)ng/mL, much higher than [(2.5±0.8)ng/mL, P<0.05] in the control group. Conclusion Acupoint application in combination with exercise in treating patients with NAFLD is short-termly efficacious, with body weight loss and reduced blood fat, which might be related to inhibition of body inflammatory reactions.

Key words: Non-alcoholic fatty liver disease, Acupoint application, Exercise prescription, Therapy

钱平安, 姜煜资, 聂红明. 穴位贴敷疗法联合运动处方治疗非酒精性脂肪性肝病患者疗效初步研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 206-209.

Qian Ping'an, Jiang Yuzi, Nie Hongming. A preliminary study on acupoint application at base of sport exercise in the treatment of patients with non-alcoholic fatty liver disease[J]. Journal of Practical Hepatology, 2025, 28(2): 206-209.

参考文献

[1] Huang DQ, El-Serag HB, Loomba R. Global epidemiology of NAFLD-related HCC: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol, 2021,18(4):223-238.
[2] Iwadare T, Kimura T, Kunimoto H,et al. Long-term pemafibrate treatment exhibits limited impact on body fat mass in patients with hypertriglyceridemia accompanying NAFLD. Front Endocrinol (Lausanne), 2024,15:1329294.
[3] 尹曼,黄新娟,张荷,等. 代谢相关脂肪性肝病患者运动依从性的研究进展. 中华健康管理学杂志,2024,18(1):68-72.
[4] Taha MM, Abdelghany AI, Draz RS. Lipidprofile response to electroacupuncture in non-alcoholic fatty liver patients with hyperlipidemia. J Acupunct Meridian Stud, 2021,14(1):21-26.
[5] Liang M, Pan Y, Zhong T,et al. Effects of aerobic, resistance, and combined exercise on metabolic syndrome parameters and cardiovascular risk factors: a systematic review and network meta-analysis. Rev Cardiovasc Med, 2021,22(4):1523-1533.
[6] 中华医学会肝病学分会.代谢相关(非酒精性)脂肪性肝病防治指南(2024年版).实用肝脏病杂志,2024,27(4): 494-510.
[7] 中国成人血脂异常防治指南修订联合委员会. 中国成人血脂异常防治指南(2016年修订版). 中华全科医师杂志,2017,16(1):15-35.
[8] Morishita A, Oura K, Takuma K,et al. Pemafibrate improves liver dysfunction and non-invasive surrogates for liver fibrosis in patients with non-alcoholic fatty liver disease with hypertriglyceridemia: a multicenter study. Hepatol Int, 2023,17(3):606-614.
[9] Hansen CD, Gram-Kampmann EM, Hansen JK, et al. Effect of calorie-unrestricted low-carbohydrate, high-fat diet versus high-carbohydrate, low-fat diet on type 2 diabetes and nonalcoholic fatty liver disease : A randomized controlled trial. Ann Intern Med, 2023,176(1):10-21.
[10] Lu CW, Yang KC, Chi YC, et al. Adiponectin-leptin ratio for the early detection of lean non-alcoholic fatty liver disease independent of insulin resistance. Ann Med, 2023,55(1):634-642.
[11] Nouri S, Navari M, Shafiee R, et al. The rs1862513 promoter variant of resistin gene influences susceptibility to nonalcoholic fatty liver disease. Rev Assoc Med Bras (1992), 2024,70(7):e20231537.
[12] Damavandi N, Zeinali S. Association of xenobiotic-metabolizing enzymes (GSTM1 and GSTT 1), and pro-inflammatory cytokines (TNF-α and IL-6) genetic polymorphisms with non-alcoholic fatty liver disease. Mol Biol Rep, 2021,48(2):1225-1231.
[13] 王芳,高晓霞,汪庆强. 黄连解毒汤联合益生菌制剂对非酒精性脂肪性肝炎患者中医症候积分和肠道菌群平衡的影响. 实用肝脏病杂志,2022,25(2):235-238.
[14] Reddy A, Gatta PD, Mason S, et al. Adherence to a Mediterranean diet may improve serum adiponectin in adults with nonalcoholic fatty liver disease: The MEDINA randomized controlled trial. Nutr Res, 2023,119:98-108.
[15] Bi Y, Yin B, Fan G, et al. Effects of acupoint therapy on nonalcoholic fatty liver disease: A systematic review and meta-analysis. Complement Ther Clin Pract, 2021,43:101376.
[16] 梁惠卿,林立,刘垚昱,等. 皂术茵陈方对非酒精性脂肪性肝炎大鼠USP18/TAK1/NF-κB信号通路的影响. 中华中医药杂志,2023,38(10):4887-4890.
[17] 刘凯利,张强,李军辉, 等. 柴胡人参药对通过调控胆汁酸代谢防治NAFLD的研究 .中华中医药学刊,2022,40(3):101-106+267.
[18] Luo L, Zhang H, Chen W, et al. Angelica sinensis polysaccharide ameliorates nonalcoholic fatty liver disease via restoring estrogen-related receptor α expression in liver. Phytother Res, 2023,37(11):5407-5417.
[19] Chen C, Yang L, Li M, et al. Study on the targeted regulation of Scutellaria baicalensis leaf on glutamine-glutamate metabolism and glutathione synthesis in the liver of D-gal ageing rats. J Pharm Pharmacol, 2023,75(9):1212-1224.
[20] Yamada Y, Saito H, Araki M, et al. Wogonin, a compound inScutellaria baicalensis, activates ATF4-FGF21 signaling in mouse hepatocyte AML12 cells. Nutrients, 2022,14(19):3920.

穴位贴敷疗法联合运动处方治疗非酒精性脂肪性肝病患者疗效初步研究^*

A preliminary study on acupoint application at base of sport exercise in the treatment of patients with non-alcoholic fatty liver disease

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吕天富, 南琼. 经颈静脉肝内门体分流术治疗肝硬化门静脉高压症患者抗凝治疗研究进展[J]. 实用肝脏病杂志, 2025, 28(2): 165-168.
[2]	陈婷婷, 丁蓉, 姬文莉, 吴梦秋. 高敏HBV DNA检测技术在低病毒血症慢性乙型肝炎患者抗病毒疗效监测中的应用^*[J]. 实用肝脏病杂志, 2025, 28(2): 178-181.
[3]	钱花, 杨忠祥, 石荔. 核苷(酸)类似物经治的慢性乙型肝炎患者发生低病毒血症影响因素分析^*[J]. 实用肝脏病杂志, 2025, 28(2): 186-189.
[4]	祁婧, 赵小婷, 王婷婷, 高瑞. 接受索磷布韦/达拉他韦治疗的慢性丙型肝炎患者血清NOD样受体热蛋白结构域相关蛋白3水平变化及其临床意义探讨^*[J]. 实用肝脏病杂志, 2025, 28(2): 194-197.
[5]	王小燕, 崔文星, 陈超. FibroTouch^©和CT定量检查诊断脂肪肝人群NASH效能研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 198-201.
[6]	韩悦, 翟菲菲, 张晴, 孟慧敏. 超声衰减成像系数诊断非酒精性脂肪性肝病患者肝脏脂肪变性程度价值研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 202-205.
[7]	吴彬彬, 李丹丹, 王子铭. 非酒精性脂肪性肝病合并2型糖尿病患者尿微量白蛋白及血清糖化血红蛋白和甲状腺激素水平变化^*[J]. 实用肝脏病杂志, 2025, 28(2): 210-213.
[8]	管海燕, 张慧, 张毅, 王晓兰, 吴婷婷. 肝脂肪变性对泼尼松与硫唑嘌呤联合治疗的自身免疫性肝炎患者治疗应答的影响^*[J]. 实用肝脏病杂志, 2025, 28(2): 214-217.
[9]	孙超, 宋丽萍, 王彬. 异甘草酸镁联合还原型谷胱甘肽治疗化疗药物性肝损伤患者疗效及其血清氧化应激指标的变化研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 222-225.
[10]	何晓非, 陈杰, 赵斌, 陆世峰. 选择性脾胃区减断术与脾切除联合贲门周围血管离断术治疗肝硬化并发门静脉高压症患者疗效对照研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 238-241.
[11]	拾倩, 李莉, 倪昊天. 替诺福韦联合安络化纤丸治疗乙型肝炎肝硬化患者临床疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 242-245.
[12]	程晓洁, 彭星华, 葛海江, 程海超, 张明, 李智峰. 脾栓塞术治疗肝豆状核变性并发中重度脾功能亢进症患者疗效评价^*[J]. 实用肝脏病杂志, 2025, 28(2): 250-253.
[13]	陈思雨, 庞永平, 宋云鹏, 乔海霞. TACE联合靶向和免疫治疗中晚期肝细胞癌患者疗效研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 258-261.
[14]	严隽瑶, 尹国文, 徐清宇, 尤然, 秦锦霞. 阿替利珠单抗联合射频消融术治疗不可切除的肝细胞癌患者临床疗效和安全性研究^*[J]. 实用肝脏病杂志, 2025, 28(2): 262-265.
[15]	钟新梅, 闫莉莉, 张冬梅. 细菌性肝脓肿患者临床特征与病原菌分析^*[J]. 实用肝脏病杂志, 2025, 28(2): 286-289.